← Back to patent-cliff list
KH-001 (Kanna Health)
Tier C — Watch / tradeKH-001 (Kanna Health)
Kanna Health Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Premature ejaculation
Regional status
US
Phase I
2023-11-16
EU
Phase I
2023-11-16
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of KH-001 (Kanna Health)?
Approved indications include: Premature ejaculation.
When does the KH-001 (Kanna Health) patent expire?
No public expiry year is available for KH-001 (Kanna Health) yet; this page updates once verified.
How do I get a quote for KH-001 (Kanna Health) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29